Harrow Health, Inc.
Harrow Health, Inc. (HROW) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
hrow · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Harrow Health, Inc. (HROW) measures how much investors pay for each dollar of the company's trailing earnings. HROW's current PE ratio of N/A is calculated by dividing its stock price of $33.10 by its TTM earnings per share of -$0.40.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Harrow Health, Inc.You HROW | $1.2B | N/A | — | -$0.40 |
 Alvotech ALVO | $1.3B | 51.30x | +38.4% | $0.10 |
 Amphastar Pharmaceuticals, Inc. AMPH | $855M | 12.76x | -65.6% | $2.10 |
 BioLife Solutions, Inc. BLFS | $1.3B | N/A | — | -$0.25 |
 Collegium Pharmaceutical, Inc. COLL | $1.1B | 23.35x | -37.0% | $1.98 |
 Dynavax Technologies Corporation DVAX | $1.8B | 60.81x | +64.1% | $0.21 |
 Evotec SE EVO | $998M | N/A | — | -$0.28 |
Industry Average 4 peers with valid PE | — | 37.06x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-0.14 | — | |
2024-12-31 FY2024 | — | $-0.49 | — | |
2023-12-31 FY2023 | — | $-0.75 | — | |
2022-12-31 FY2022 | — | $-0.51 | — | |
2021-12-31 FY2021 | — | $-0.67 | — | |
2020-12-31 FY2020 | — | $-0.13 | — | |
2019-12-31 FY2019 | 1172.70x | $0.01 | +13652.1% | |
2018-12-31 FY2018 | 8.53x | $0.67 | — | |
2017-12-31 FY2017 | — | $-0.60 | — | |
2016-12-31 FY2016 | — | $-1.50 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Harrow Health, Inc. (HROW) measures how much investors pay for each dollar of the company's trailing earnings. HROW's current PE ratio of N/A is calculated by dividing its stock price of $33.10 by its TTM earnings per share of -$0.40.
Frequently asked questions
HROW pe ratio · 6 questionsHROW's current PE ratio is N/A as of 2026-06-08, based on a stock price of $33.10 and TTM EPS of -$0.40. Data sourced from Financial Modeling Prep via HROW's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Harrow Health, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08